Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDWCM2)

• Drug Name: Rilvegostomig Drug Info
• Synonyms: AZD2936

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMDWCM2

Molecule-Related Drug Atlas

Drug(s) Targeting V-set and immunoglobulin domain-containing protein 9 (TIGIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ociperlimab	DMEDSVJ	Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
AB154	DMUES7Y	Non-small-cell lung cancer	2C25	Phase 3	[3]
GSK4428859	DMIOIU8	Aggressive cancer	2A00-2F9Z	Phase 2	[4]
ASP8374	DMA71OL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
SEA-TGT	DM7GUH3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
COM902	DMR6T8L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
M6223	DM6J085	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[9]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[10]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[9]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[11]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[12]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[13]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[14]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[15]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[16]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[1]
V-set and immunoglobulin domain-containing protein 9 (TIGIT)	TTWNL74	TIGIT_HUMAN	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of BeiGene.
• [3] Clinical pipeline report, company report or official report of Arcus Biosciences.
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of Seagen.
• [7] COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
• [8] ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.
• [9] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [10] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [11] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [15] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [16] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)